Program
trichostatin A
Its studies are mostly in Hematologic Neoplasms · Onychomycosis, led by Vanda Pharmaceuticals.
Furthest: phase 2, since Jun 5, 20252 company-led studies, 2 open or runningNext primary completion: Dec 2027 (phase 1)
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Vanda Pharmaceuticals | 22 open or running | phase 2since Jun 5, 2025 | Feb 11, 2019 | Dec 2027phase 1 · NCT03838926 |
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Feb 11, 2019First study: phase 1 study in RecurrenceFirst studyNCT03838926 · 42 planned · United States, Poland
- Jun 5, 2025Phase 2 study in OnychomycosisNCT07065773 · 50 enrolled · United States
Ahead
- Dec 2027Primary completion: phase 1 study in RecurrenceNCT03838926
TargetBeta
Not stated by its company or a source we have read. Most early programs say nothing of it.
Studies
All 2 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07065773Onychomycosis · United States | 2 | Active, not recruiting | Sep 2026 | 50 |
| NCT03838926Recurrence · United States, Poland | 1 | Recruiting | Dec 2027 | 42 |
How it is read
Names in the registry
- “Trichostatin A”, 2 entries
Conditions, from the studies’ own filings
- Hematologic Neoplasms, 1 study
- Onychomycosis, 1 study
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.